Evidence map›Paper›PMID 40293475›Full record

ArticleArchives of toxicology2025

Application of a high-density microelectrode array assay using a 3D human iPSC-derived brain microphysiological system model for in vitro neurotoxicity screening of environmental compounds.

Kelly E Carstens, Elena Gronskaya, David Jäckel, Jessica Bertoli, Kelvin Ramirez Cuevas, Julien Dorier, Shan Wang, David Lopez-Rodriguez, Timothy J Shafer, Marie-Gabrielle Zurich and 1 more

Abstract read
In one paragraph

Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Neurotoxic mechanisms of cadmium in neurodegenerative diseases.Frontiers in cell and developmental biology · 2026
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kelly E CarstensCenter for Computational Toxicology and Exposure, USA Environmental Protection Agency, Research Triangle Park, North Carolina, NC, 27707, USA.
Elena GronskayaMaxWell Biosystems AG, Zurich, Switzerland.
David JäckelMaxWell Biosystems AG, Zurich, Switzerland.
Jessica BertoliDepartment of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.
Kelvin Ramirez CuevasDepartment of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.
Julien DorierBioinformatics Competence Center, University of Lausanne, CH- 1015, Lausanne, Switzerland.
Shan WangDepartment of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.
David Lopez-RodriguezDepartment of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.
Timothy J ShaferCenter for Computational Toxicology and Exposure, USA Environmental Protection Agency, Research Triangle Park, North Carolina, NC, 27707, USA.
Marie-Gabrielle ZurichDepartment of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.
David PamiesDepartment of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland. David.pamies@unil.ch.ORCID 0000-0002-1224-573X

Funding

Swiss Centre for Applied Human Toxicology AP20-4
6 · The paper itself

Abstract

Unraveling the associations between human exposure to environmental chemicals and potential neurotoxicity presents significant challenges. Evaluation of neurotoxicity potential using animal testing is resource-intensive (financial, labor, and animal use) and faces uncertainties regarding biological relevance to human health outcomes. Therefore, there is a need to develop efficient and human-relevant in vitro new approach methodologies (NAMs) to screen and evaluate chemicals for neurotoxicity potential. Recording of neural network activity using microelectrode array (MEA) technology has been identified as a reliable and reproducible method for evaluating neurotoxicity. Much of this research has been performed in 2D rodent-derived cell models. The 'BrainSpheres MEA assay' described in this study offers a promising functional human induced pluripotent stem cell (iPSC)-derived 3D brain model comprising neurons, astrocytes, and oligodendrocytes. We demonstrate consistent spontaneous neuronal firing and network bursting parameters from 7-week-old BrainSpheres using a high-density MEA technology. The performance of this model as a human-relevant NAM was evaluated by conducting a multi-concentration, 13 day exposure study with a set of ten chemicals. Neural activity metrics were assessed and compared to results from a 2D-MEA assay using rodent cells. Loperamide and domoic acid (two assay positive controls) demonstrated similar bioactivity profiles in the BrainSphere MEA assay to the 2D-MEA assay, while acetaminophen (assay negative control) was inactive in both assays. The 2D-MEA model demonstrated more potent bioactivity for 4/7 chemicals that were active in both assays. In the future, reducing replicate variability and testing a larger set of chemicals will likely improve the accuracy and reliability of the assay. These preliminary findings suggest that the BrainSphere assay could be used alongside the rat network formation assay (rNFA) as part of a tiered strategy, where hits in the rNFA are confirmed and further characterized in the BrainSphere model, helping move toward animal-free toxicological testing.

Indexed as

BrainEnvironmental PollutantsInduced Pluripotent Stem CellsNeurotoxicity SyndromesToxicity TestsAstrocytesCells, CulturedHumansMicroelectrodesMicrophysiological SystemsNeuronsOligodendrogliaEnvironmental Pollutants3D culturesBrainSphereHigh-density electrode arrayiPSCMEAMicroelectrode arrayMPSNeuronal electrical activityNeurotoxicology

Identifiers

PMID40293475
PMCPMC12198282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.